FAST NEWS: HutchMed Shares Plunge on U.S. Cancer Drug Rejection
The latest: HutchMed (China) Ltd. (HCM.US; 0013.HK) announced late Monday that its Surufatinib drug for the treatment of advanced neuroendocrine tumors was denied approval by the U.S. Food and Drug…
Biotech Aspirant Hutchmed Sails Full Steam Toward Hong Kong Homecoming IPO
Company backed by billionaire Li Ka-shing secures cornerstone investors for more than half of its $600 million secondary listing in its home market Key points: • Hutchmed announces new approvals…
RELATED ARTICLES
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
